William Blair analyst Matt Phipps has maintained their bullish stance on EVMN stock, giving a Buy rating on May 1.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matt Phipps has given his Buy rating due to a combination of factors tied to Evommune’s advancing pipeline and upcoming catalysts. He highlights that patient enrollment is finished in both Phase IIb trials of EVO756 in chronic spontaneous urticaria and atopic dermatitis, with the CSU efficacy data expected by late June 2026 and AD results to follow in the third quarter, creating a near-term value inflection point.
He also points to the company’s deliberate expansion of its MRGPRX2 program into migraine, where a Phase IIb trial is slated to begin in mid-2026, and to the strong proof-of-concept data for EVO301 in atopic dermatitis that support a larger Phase IIb dose-ranging study once manufacturing and toxicology work on the subcutaneous formulation are completed. Together, these clinical milestones and the diversified late-stage pipeline underpin his positive view of Evommune’s risk‑reward profile and support the Buy recommendation.
In another report released on May 1, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $54.00 price target.